ArticleJournal of clinical microbiology2009
Armored long RNA controls or standards for branched DNA assay for detection of human immunodeficiency virus type 1.
Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 59 citations in OpenAlex.
- Development, Characterization, and Validation of an MS2 Phage-Based Armored RNA Control for Schmallenberg Virus Detection.Pathogens (Basel, Switzerland) · 2026Article
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
- Armored RNA technology as a clinical diagnostics tool for future pandemic preparedness.Journal of microbiology (Seoul, Korea) · 2026Review
- The RNA Landscape of In Vivo-Assembled MS2 Virus-Like Particles as mRNA Carriers Reveals RNA Contamination from Host Viruses.Nano letters · 2025Article
- Simplified MS2 phage-like particle production including a novel maturation protein internal fusion affinity tag.Biotechnology, biotechnological equipment · 2025Article
- MS2 virus-like particles as a versatile platform for multi-disease vaccines: a review.Frontiers in immunology · 2025Review
- Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells.Nanomedicine (London, England) · 2024Review
- Assessing the comparability of cycle threshold values derived from five external quality assessment rounds for omicron nucleic acid testing.Virology journal · 2023Article
- Current status and progress of the development of prostate cancer vaccines.Journal of Cancer · 2023Review
- Simple Low-Cost Production of DNA MS2 Virus-Like Particles As Molecular Diagnostic Controls.GEN biotechnology · 2022Article
- Programmable polymorphism of a virus-like particle.Communications materials · 2022Article
- Optimizing the synthesis and purification of MS2 virus like particles.Scientific reports · 2021Article
- External Quality Assessment for Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Clinical Laboratories.The Journal of molecular diagnostics : JMD · 2021Article
- Bacteriophage MS2 displays unreported capsid variability assembling T = 4 and mixed capsids.Molecular microbiology · 2020Article
- Development and Evaluation of a Novel Armored RNA Technology Using Bacteriophage Qβ.Food and environmental virology · 2019Article
- External quality assessment for PML-RARα detection in acute promyelocytic leukemia: Findings and summary.Journal of clinical laboratory analysis · 2019Article
- Development and evaluation of armored RNA-based standards for quantification of BCR-ABL1Journal of clinical laboratory analysis · 2018Article
- Preparation and Evaluation of Ribonuclease-Resistant Viral HIV RNA Standards Based on Armored RNA TechnologyIranian biomedical journal · 2018Article
- One-plasmid double-expression His-tag system for rapid production and easy purification of MS2 phage-like particles.Scientific reports · 2017Article
- Internal control for real-time polymerase chain reaction based on MS2 bacteriophage for RNA viruses diagnostics.Memorias do Instituto Oswaldo Cruz · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The branched DNA (bDNA) assay is a reliable method for quantifying the RNA of human immunodeficiency virus type 1 (HIV-1). The positive controls and standards for this assay for the detection of HIV-1 consist of naked RNA, which is susceptible to degradation by RNase. Armored RNA is a good candidate for an RNase-resistant positive control or standard. However, its use has been limited by the maximal length of the exogenous RNA packaged into virus-like particles by routine armored RNA technology. In the present study, we produced armored long RNA (armored L-RNA) controls or standards (AR-HIV-pol-3034b) for a bDNA assay of HIV-1 by increasing the amount and affinity of the pac sites (the pac site is a specific 19-nucleotide stem-loop region located at the 5' terminus of the MS2 bacteriophage replicase gene) by a one-plasmid double-expression system. AR-HIV-pol-3034b was completely resistant to DNase and RNase, was stable in normal human EDTA-preserved plasma at 4 degrees C for at least 6 months, and produced reproducible, linear results in the Versant HIV-1 RNA 3.0 assay. In conclusion, AR-HIV-pol-3034b could act as a positive control or standard in a bDNA assay for the detection of HIV-1. In addition, the one-plasmid double-expression system can be used as a better platform than the one-plasmid expression system and the two-plasmid coexpression system for expressing armored L-RNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.